Aspirin for the Primary Prevention of Cardiovascular Disease in Women

Alison L. Bailey, Charles Campbell, Susan S. Smyth

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Primary prevention of cardiovascular disease, which is the leading cause of death of women in the United States, focuses on treating or eliminating risk factors and often includes the use of aspirin to prevent thrombotic complications of atherosclerosis or atrial fibrillation. Recent evidence reveals sex-based differences in the benefits of aspirin in individuals without established cardiovascular disease. Although use of aspirin does not affect total mortality in either sex, aspirin lowers the risk of ischemic stroke in women and decreases the risk of myocardial infarction in men. Unfortunately, the use of aspirin comes at the expense of an increase in bleeding events, mostly gastrointestinal, that occurs at roughly similar rates in women and men. Aspirin may not be beneficial for primary prevention of cardiovascular events in women with diabetes. The benefits, as well as the risks, of aspirin therapy should be discussed when contemplating the use of aspirin in the primary prevention of cardiovascular disease in women.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalCurrent Cardiovascular Risk Reports
Volume4
Issue number3
DOIs
StatePublished - Mar 10 2010
Externally publishedYes

Fingerprint

Primary Prevention
Aspirin
Cardiovascular Diseases
Sex Characteristics
Atrial Fibrillation
Cause of Death
Atherosclerosis
Stroke
Myocardial Infarction
Hemorrhage
Mortality

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aspirin for the Primary Prevention of Cardiovascular Disease in Women. / Bailey, Alison L.; Campbell, Charles; Smyth, Susan S.

In: Current Cardiovascular Risk Reports, Vol. 4, No. 3, 10.03.2010, p. 209-215.

Research output: Contribution to journalReview article

@article{d6b1fed8ae0440b499609817045bddf6,
title = "Aspirin for the Primary Prevention of Cardiovascular Disease in Women",
abstract = "Primary prevention of cardiovascular disease, which is the leading cause of death of women in the United States, focuses on treating or eliminating risk factors and often includes the use of aspirin to prevent thrombotic complications of atherosclerosis or atrial fibrillation. Recent evidence reveals sex-based differences in the benefits of aspirin in individuals without established cardiovascular disease. Although use of aspirin does not affect total mortality in either sex, aspirin lowers the risk of ischemic stroke in women and decreases the risk of myocardial infarction in men. Unfortunately, the use of aspirin comes at the expense of an increase in bleeding events, mostly gastrointestinal, that occurs at roughly similar rates in women and men. Aspirin may not be beneficial for primary prevention of cardiovascular events in women with diabetes. The benefits, as well as the risks, of aspirin therapy should be discussed when contemplating the use of aspirin in the primary prevention of cardiovascular disease in women.",
author = "Bailey, {Alison L.} and Charles Campbell and Smyth, {Susan S.}",
year = "2010",
month = "3",
day = "10",
doi = "10.1007/s12170-010-0097-5",
language = "English (US)",
volume = "4",
pages = "209--215",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Aspirin for the Primary Prevention of Cardiovascular Disease in Women

AU - Bailey, Alison L.

AU - Campbell, Charles

AU - Smyth, Susan S.

PY - 2010/3/10

Y1 - 2010/3/10

N2 - Primary prevention of cardiovascular disease, which is the leading cause of death of women in the United States, focuses on treating or eliminating risk factors and often includes the use of aspirin to prevent thrombotic complications of atherosclerosis or atrial fibrillation. Recent evidence reveals sex-based differences in the benefits of aspirin in individuals without established cardiovascular disease. Although use of aspirin does not affect total mortality in either sex, aspirin lowers the risk of ischemic stroke in women and decreases the risk of myocardial infarction in men. Unfortunately, the use of aspirin comes at the expense of an increase in bleeding events, mostly gastrointestinal, that occurs at roughly similar rates in women and men. Aspirin may not be beneficial for primary prevention of cardiovascular events in women with diabetes. The benefits, as well as the risks, of aspirin therapy should be discussed when contemplating the use of aspirin in the primary prevention of cardiovascular disease in women.

AB - Primary prevention of cardiovascular disease, which is the leading cause of death of women in the United States, focuses on treating or eliminating risk factors and often includes the use of aspirin to prevent thrombotic complications of atherosclerosis or atrial fibrillation. Recent evidence reveals sex-based differences in the benefits of aspirin in individuals without established cardiovascular disease. Although use of aspirin does not affect total mortality in either sex, aspirin lowers the risk of ischemic stroke in women and decreases the risk of myocardial infarction in men. Unfortunately, the use of aspirin comes at the expense of an increase in bleeding events, mostly gastrointestinal, that occurs at roughly similar rates in women and men. Aspirin may not be beneficial for primary prevention of cardiovascular events in women with diabetes. The benefits, as well as the risks, of aspirin therapy should be discussed when contemplating the use of aspirin in the primary prevention of cardiovascular disease in women.

UR - http://www.scopus.com/inward/record.url?scp=84873524136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873524136&partnerID=8YFLogxK

U2 - 10.1007/s12170-010-0097-5

DO - 10.1007/s12170-010-0097-5

M3 - Review article

VL - 4

SP - 209

EP - 215

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 3

ER -